To provide suggestions to complete the incentive policy of biopharmaceutical technology innovation in China, we established an incentive policy and appraisal system aiming at evaluating implemented effect of the policy above and sample related indexes of the countries whose bio-pharmaceutical industry was relatively developed as comparison objects. Results showed that policy of intellectual property right of medicine and drug registration which were set to stimulate the technology innovation of biopharmaceutical in China needed to be better perfected. The gap of biopharmaceutical innovation level between China and the developed countries is large, while adjusting related incentive policy is the main guarantee to stimulate the R&D input and output.%为完善我国生物医药技术创新激励政策提供建议,建立生物医药技术创新激励政策及其实施效果评价指标体系,并选取生物医药创新水平较高国家的相关指标进行对比分析.结果显示,我国的药品知识产权政策、药品注册审批政策等在激励生物医药技术创新方面还有待进一步完善.我国生物医药技术创新水平与国外发达国家相比还存在较大差距,调整相关激励政策是激励创新药物研发投入进而激励其产出的重要保证.
展开▼
